{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:27:07Z","timestamp":1775039227290,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Trotz jahrzehntelanger Forschung und gesellschaftlichen Interesses sind die Verh\u00fctungsoptionen f\u00fcr den Mann stark eingeschr\u00e4nkt. Seit Frauen von hormonellen Methoden profitieren, liegt die Hauptverantwortung f\u00fcr Kontrazeption nahezu ausschlie\u00dflich bei ihnen. Angesichts m\u00f6glicher Nebenwirkungen weiblicher Hormonpr\u00e4parate und des Rechts auf k\u00f6rperliche Selbstbestimmung r\u00fcckt die Entwicklung sicherer, reversibler Methoden f\u00fcr M\u00e4nner in den Fokus.<\/jats:p>\n                  <jats:p>Die hormonelle Kontrazeption beim Mann basiert auf der Suppression der Spermienbildung durch exogenes Testosteron in Kombination mit Gestagenen. Multicenterstudien mit Testosteronundecanoat und Norethisteron-Enantat zeigten eine kontrazeptive Wirksamkeit, die oralen Kontrazeptiva der Frau entspricht. Nebenwirkungen wie Libidoverlust, depressive Verstimmungen und Gewichtszunahme f\u00fchrten zum Abbruch der World Health Organization (WHO)-gef\u00fchrten Studie. Transdermale Gelkombinationen (Testosteron\/Nestoron) und neue orale Wirkstoffe zeigen ein g\u00fcnstigeres Vertr\u00e4glichkeitsprofil.<\/jats:p>\n                  <jats:p>Parallel gewinnen nichthormonelle Ans\u00e4tze an Bedeutung. Dazu z\u00e4hlen Retins\u00e4ure-Rezeptor-(RAR\u03b1\u2011)Antagonisten wie YCT-529, die die Spermatogenese gezielt hemmen, sowie Inhibitoren der l\u00f6slichen Adenylatzyklase (sAC), die eine bedarfsgerechte Kontrazeption durch reversible Hemmung der Spermienmotilit\u00e4t erm\u00f6glichen. Beide Strategien erwiesen sich in pr\u00e4klinischen Studien als hochwirksam, reversibel und gut vertr\u00e4glich; YCT-529 befindet sich in klinischer Erprobung.<\/jats:p>\n                  <jats:p>Die Entwicklung m\u00e4nnlicher Kontrazeptiva wird aktuell von akademischen und gemeinn\u00fctzigen Institutionen vorangetrieben. Obwohl marktreife Pr\u00e4parate noch ausstehen, verdeutlichen die Fortschritte in hormonellen und nichthormonellen Ans\u00e4tzen das Potenzial f\u00fcr eine gerechtere Verteilung der Verh\u00fctungsverantwortung.<\/jats:p>","DOI":"10.1007\/s00103-026-04208-8","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:38:38Z","timestamp":1772116718000},"page":"410-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kontrazeption f\u00fcr den Mann\u00a0\u2013 Wissenschaftliche Erkenntnisse und Entwicklungen","Male contraception\u2014scientific foundations and contemporary progress"],"prefix":"10.1007","volume":"69","author":[{"given":"Michael","family":"Zitzmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"4208_CR1","unstructured":"Alan Guttmacher Institute (2003) In their own right: Addressing the sexual and reproductive health needs of men worldwide. https:\/\/www.guttmacher.org\/report\/their-own-right-addressing-sexual-and-reproductive-health-needs-men-worldwide. Accessed 4.12.2025"},{"key":"4208_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/humrep\/deh574","volume":"20","author":"K Heinemann","year":"2005","unstructured":"Heinemann\u00a0K, Saad\u00a0F, Wiesemes\u00a0M, White\u00a0S, Heinemann\u00a0L (2005) Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 20:549\u2013556. https:\/\/doi.org\/10.1093\/humrep\/deh574","journal-title":"Hum Reprod"},{"key":"4208_CR3","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1210\/jc.2007-2768","volume":"93","author":"PY Liu","year":"2008","unstructured":"Liu\u00a0PY, Swerdloff\u00a0RS, Anawalt\u00a0BD et\u00a0al (2008) Determinants of the rate and extent of spermatogenic suppression during hormonal male contraception: an integrated analysis. J\u00a0Clin Endocrinol Metab 93:1774\u20131783. https:\/\/doi.org\/10.1210\/jc.2007-2768","journal-title":"J Clin Endocrinol Metab"},{"key":"4208_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/humrep\/15.3.646","volume":"15","author":"AF Glasier","year":"2000","unstructured":"Glasier\u00a0AF, Anakwe\u00a0R, Everington\u00a0D et\u00a0al (2000) Would women trust their partners to use a male pill? Hum Reprod 15:646\u2013649. https:\/\/doi.org\/10.1093\/humrep\/15.3.646","journal-title":"Hum Reprod"},{"key":"4208_CR5","unstructured":"Zitzmann M (2025) Verh\u00fctung beim Mann \u2013 aktueller Stand. https:\/\/www.der-niedergelassene-arzt.de\/medizin-und-forschung\/details\/verhuetung-beim-mann-aktueller-stand-1\/1. Accessed 4.12.2025"},{"key":"4208_CR6","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1210\/er.2002-0002","volume":"23","author":"RA Anderson","year":"2002","unstructured":"Anderson\u00a0RA, Baird\u00a0DT (2002) Male contraception. Endocr Rev 23:735\u2013762. https:\/\/doi.org\/10.1210\/er.2002-0002","journal-title":"Endocr Rev"},{"key":"4208_CR7","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S0039-128X(03)00135-1","volume":"68","author":"E Nieschlag","year":"2003","unstructured":"Nieschlag\u00a0E, Zitzmann\u00a0M, Kamischke\u00a0A (2003) Use of progestins in male contraception. Steroids 68:965\u2013972. https:\/\/doi.org\/10.1016\/S0039-128X(03)00135-1","journal-title":"Steroids"},{"key":"4208_CR8","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1210\/jc.2004-0895","volume":"90","author":"CJ Hay","year":"2005","unstructured":"Hay\u00a0CJ, Brady\u00a0BM, Zitzmann\u00a0M et\u00a0al (2005) A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception. J\u00a0Clin Endocrinol Metab 90:2042\u20132049. https:\/\/doi.org\/10.1210\/jc.2004-0895","journal-title":"J Clin Endocrinol Metab"},{"key":"4208_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/humrep\/dei300","volume":"21","author":"BM Brady","year":"2006","unstructured":"Brady\u00a0BM, Amory\u00a0JK, Perheentupa\u00a0A et\u00a0al (2006) A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod 21:285\u2013294. https:\/\/doi.org\/10.1093\/humrep\/dei300","journal-title":"Hum Reprod"},{"key":"4208_CR10","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1210\/jc.2008-0265","volume":"93","author":"E Mommers","year":"2008","unstructured":"Mommers\u00a0E, Kersemaekers\u00a0WM, Elliesen\u00a0J et\u00a0al (2008) Male hormonal contraception: a double-blind, placebo-controlled study. J\u00a0Clin Endocrinol Metab 93:2572\u20132580. https:\/\/doi.org\/10.1210\/jc.2008-0265","journal-title":"J Clin Endocrinol Metab"},{"key":"4208_CR11","doi-asserted-by":"publisher","first-page":"6603","DOI":"10.1210\/jc.2005-0847","volume":"90","author":"M Zitzmann","year":"2005","unstructured":"Zitzmann\u00a0M, Erren\u00a0M, Kamischke\u00a0A, Simoni\u00a0M, Nieschlag\u00a0E (2005) Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men. J\u00a0Clin Endocrinol Metab 90:6603\u20136608. https:\/\/doi.org\/10.1210\/jc.2005-0847","journal-title":"J Clin Endocrinol Metab"},{"key":"4208_CR12","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1210\/jc.2008-1846","volume":"94","author":"Y Gu","year":"2009","unstructured":"Gu\u00a0Y, Liang\u00a0X, Wu\u00a0W et\u00a0al (2009) Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men. J\u00a0Clin Endocrinol Metab 94:1910\u20131915. https:\/\/doi.org\/10.1210\/jc.2008-1846","journal-title":"J Clin Endocrinol Metab"},{"key":"4208_CR13","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(06)68614-5","volume":"367","author":"PY Liu","year":"2006","unstructured":"Liu\u00a0PY, Swerdloff\u00a0RS, Christenson\u00a0PD, Handelsman\u00a0DJ, Wang\u00a0C, Hormonal Male Contraception Summit Group (2006) Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367:1412\u20131420. https:\/\/doi.org\/10.1016\/S0140-6736(06)68614-5","journal-title":"Lancet"},{"key":"4208_CR14","doi-asserted-by":"publisher","first-page":"4779","DOI":"10.1210\/jc.2016-2141","volume":"101","author":"HM Behre","year":"2016","unstructured":"Behre\u00a0HM, Zitzmann\u00a0M, Anderson\u00a0RA et\u00a0al (2016) Efficacy and safety of an injectable combination hormonal contraceptive for men. J\u00a0Clin Endocrinol Metab 101:4779\u20134788. https:\/\/doi.org\/10.1210\/jc.2016-2141","journal-title":"J Clin Endocrinol Metab"},{"key":"4208_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/andr.12328","volume":"5","author":"M Zitzmann","year":"2017","unstructured":"Zitzmann\u00a0M, Rohayem\u00a0J, Raidt\u00a0J et\u00a0al (2017) Impact of various progestins with or without transdermal testosterone on gonadotropin levels for non-invasive hormonal male contraception: a randomized clinical trial. Andrology 5:516\u2013526. https:\/\/doi.org\/10.1111\/andr.12328","journal-title":"Andrology"},{"key":"4208_CR16","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/andr.12603","volume":"6","author":"BD Anawalt","year":"2019","unstructured":"Anawalt\u00a0BD, Roth\u00a0MY, Ceponis\u00a0J et\u00a0al (2019) Combined nestorone-testosterone gel suppresses serum gonadotropins to concentrations associated with effective hormonal contraception in men. Andrology 6:878\u2013887. https:\/\/doi.org\/10.1111\/andr.12603","journal-title":"Andrology"},{"key":"4208_CR17","doi-asserted-by":"crossref","unstructured":"Amory JK, Blithe DL, Ware RS et\u00a0al. (2023) Design of an international male contraceptive efficacy trial using a\u00a0self-administered daily transdermal gel containing testosterone and segesterone acetate (Nestorone\u00ae). Contraception 110064. https:\/\/doi.org\/10.1016\/j.contraception.2023.110064","DOI":"10.1016\/j.contraception.2023.110064"},{"key":"4208_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1210\/jc.2018-01452","volume":"104","author":"A Thirumalai","year":"2019","unstructured":"Thirumalai\u00a0A, Ceponis\u00a0J, Amory\u00a0JK et\u00a0al (2019) Effects of 28 days of oral dimethandrolone undecanoate in healthy men: a prototype male pill. J\u00a0Clin Endocrinol Metab 104:423\u2013432. https:\/\/doi.org\/10.1210\/jc.2018-01452","journal-title":"J Clin Endocrinol Metab"},{"key":"4208_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.contraception.2021.06.009","volume":"104","author":"BT Nguyen","year":"2021","unstructured":"Nguyen\u00a0BT, Yuen\u00a0F, Farrant\u00a0M et\u00a0al (2021) Acceptability of the oral hormonal male contraceptive prototype, 11\u03b2-methyl-19-nortestosterone dodecylcarbonate (11\u03b2-MNTDC), in a 28-day placebo-controlled trial. Contracept X 104:531\u2013537. https:\/\/doi.org\/10.1016\/j.contraception.2021.06.009","journal-title":"Contraception"},{"key":"4208_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-00752-7","volume":"5","author":"N Mannowetz","year":"2025","unstructured":"Mannowetz\u00a0N, Chung\u00a0SSW, Maitra\u00a0S et\u00a0al (2025) Targeting the retinoid signaling pathway with YCT-529 for effective and reversible oral contraception in mice and primates. Commun Med 5:68. https:\/\/doi.org\/10.1038\/s43856-025-00752-7","journal-title":"Commun Med (Lond)"},{"issue":"1","key":"4208_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36119-6","volume":"14","author":"M Balbach","year":"2023","unstructured":"Balbach\u00a0M, Rossetti\u00a0T, Ferreira\u00a0J et\u00a0al (2023) On-demand male contraception via acute inhibition of soluble adenylyl cyclase. Nat Commun 14(1):637. https:\/\/doi.org\/10.1038\/s41467-023-36119-6","journal-title":"Nat Commun"},{"key":"4208_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/biom15040601","volume":"15","author":"N S","year":"2025","unstructured":"S\u00a0N, Gervasi\u00a0MG, Tourzani\u00a0DA et\u00a0al (2025) Identification of TSSK1 and TSSK2 as Novel Targets for Male Contraception. Biomolecules 15:601. https:\/\/doi.org\/10.3390\/biom15040601","journal-title":"Biomolecules"},{"key":"4208_CR23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2212338120","volume":"120","author":"M Lyon","year":"2023","unstructured":"Lyon\u00a0M, Li\u00a0P, Ferreira\u00a0JJ et\u00a0al (2023) A selective inhibitor of the sperm-specific potassium channel SLO3 impairs human sperm function. PNAS Nexus 120:e2217490120. https:\/\/doi.org\/10.1073\/pnas.2212338120","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-026-04208-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-026-04208-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-026-04208-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:22:19Z","timestamp":1775031739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-026-04208-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4208"],"URL":"https:\/\/doi.org\/10.1007\/s00103-026-04208-8","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Zitzmann gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}